Functional Gastrointestinal Disorders, Vagus Nerve Autonomic Disorder, Irritable Bowel Syndrome, Nausea, Dyspepsia
Conditions
Brief summary
The purpose of this study is to see if using a micro-current through a device called a TENS (Transcutaneous Electrical Nerve Stimulator) unit helps to improve functional gastrointestinal disorder (FGID) symptoms in children by stimulation of the vagus nerve. The study will compare two methods of stimulation to determine if there is a difference in the two methods.
Interventions
Active Transcutaneous Auricular Microstimulation delivered by TENS device
Sham therapy will be delivered by applying the TENS device with non-conductive electrodes so that no microstimulation is delivered
Sponsors
Study design
Masking description
Participants will be sent home at baseline with a TENS unit and a sealed envelope with instructions for device settings. The envelope will contain instructions for either sham stimulation or active stimulation (unknown to the performing coordinator and participant). Both groups will receive a new device and another set of instructions from the study team at 4 weeks. It is possible and permitted that the performing study coordinator will become aware of which group the subject is in when checking in on the subject.
Intervention model description
30 participants will be enrolled in this double-blind sham control study. Fifteen participants will undergo sham stimulation for 4 weeks followed by active microstimulation for 4 weeks. The other 15 participants will have active microstimulation for all 8 weeks.
Eligibility
Inclusion criteria
* Female patients 12-18 years old with chronic idiopathic nausea, function abdominal pain, dyspepsia and/or irritable bowel syndrome * English Speaking
Exclusion criteria
* Patients who are unable to stand upright during the heart rate variability recording * Patients with a known bleeding disorder * Gastric or cardiac pacer or defibrillator * Poor circulation in lower limbs * Swollen or inflamed outer ear * Epilepsy * Abdominal or inguinal hernia * Any unstable medical condition, such as renal disease, uncontrolled diabetes, etc. * Requires new medication during the 8 weeks of the study that may affect gastrointestinal symptoms, vagal modulation or immune response * Inability to answer questionnaires or report pain on a 0-10 visual analog scale.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Heart Rate Variability at 4 Weeks | Assessed at baseline, week 4, and week 8. Change in baseline to week 4 is reported. | EKG tracing will be used to analyze Heart Rate Variability as an indirect measure of vagal nerve output and central autonomic control. |
| Change in Heart Rate Variability at 8 Weeks | Assessed at baseline, week 4, and week 8. Change in baseline to week 8 is reported. | EKG tracing will be used to analyze Heart Rate Variability as an indirect measure of vagal nerve output and central autonomic control. |
| Change in Mitochondrial Bioenergetics Measured by Basal Oxygen Consumption Rate at 4 Weeks (Basal Consumption) | Assessed at baseline, week 4, and week 8. Change in baseline to week 4 is reported. | Blood draw will be tested for mitochondrial function by Seahorse assay, which measures Basal Oxygen Consumption Rate of live cells to provide insight into mitochondrial activity. |
| Change in Mitochondrial Bioenergetics Measured by Basal Oxygen Consumption Rate at 8 Weeks (Basal Consumption) | Assessed at baseline, week 4, and week 8. Change in baseline to week 8 is reported. | Blood draw will be tested for mitochondrial function by Seahorse assay, which measures Basal Oxygen Consumption Rate of live cells to provide insight into mitochondrial activity. |
| Change in Blood Cytokines Measured by TNF α Levels at 4 Weeks | Assessed at baseline, week 4, and week 8. Change in baseline to week 4 is reported. | Blood will be analyzed to detect changes in protein cytokine TNF α levels, an indicator for inflammation. |
| Change in Blood Cytokines Measured by TNF α Levels at 8 Weeks | Assessed at baseline, week 4, and week 8. Change in baseline to week 8. | Blood will be analyzed to detect changes in protein cytokine TNF α levels, an indicator for inflammation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Functional Disability Inventory (Child and Adolescent) | Assessed at baseline, week 4, and week 8. Score changes from baseline to week 4 and baseline to week 8 are reported. | The Functional Disability Inventory (FDI) Child and Adolescent questionnaire will be used to assess change in symptoms. Participants will rank physical trouble or difficulty completing 15 different daily activities (Eating regular meals, Being at school all day, Walking up stairs, etc.) on a scale of 0-4 for each item (0-No trouble, 1- A Little Trouble, 2- Some Trouble, 3- A Lot of Trouble, 4- Impossible). Higher total scores indicate more difficulty functioning due to physical health, based on a sum score of each item. Sum score interpretation cutoffs include: No/Minimal Disability (0-12), Mild Disability (13-20), Moderate Disability (21-29) and Severe Disability (≥30). |
| Change From Baseline in Symptom Intensity Questionnaire | Assessed at baseline, week 4, and week 8. Changes per symptom score in baseline to week 4 and baseline to week 8 are reported. | Symptom Intensity Questionnaire score will be used to identify the most prominent 5 complaints, with intensity rated on a 10-point centimeter Likert scale. Participants write up to 5 of their most severe symptoms, and then rate those symptoms' severity from none (0) to worst you can possibly imagine (10) by placing a vertical line on the scale. Higher symptom ratings reflect higher symptom intensity & frequency. A 1-3 frequency level is a minimum level and indicates symptoms are occasional. A 4-6 frequency is a moderate level, meaning that symptoms are intermittent, coming and going. A 7-8 frequency is an indication that the symptoms are present more often than not but still not constant. A 9-10 frequency level is severe and indicates that symptoms are constant. The electronic data capture system's field validation used during the study automatically translated the participant-facing 0-10 slider scale placement into a score of 0-100, hence the reported mean values of over 10. |
| Change From Baseline in Pain Catastrophizing Scale (Child) | Assessed at baseline, week 4, and week 8. Score change in baseline to week 8 is reported. | The Pain Catastrophizing Scale Child form (PCS-C) will be completed by the participant. The PCS-C is a modification of the adult Pain Catastrophizing Scale for use in children, measuring pain-related cognitions and the dimensions of helplessness, rumination and magnification. Participants rate how strong their feelings are about pain on a 5 point scale (0- Not at all, 1- To a slight degree, 2- To a moderate degree, 3- To a great degree, 4- All the time). Sum scores range from 0-52. Higher scores indicate higher levels of pain catastrophizing. A total PCS score of 30 represents a clinically relevant level of catastrophizing. |
| Change From Baseline in Revised Child Anxiety and Depression Scale | Assessed at baseline, week 4, and week 8. Changes in generalized anxiety & depression t-scores (translated from raw subscale scores) in baseline to week 4 and baseline to week 8 are reported. | The Revised Child Anxiety and Depression Scale (RCADS) assesses children grades 3 to 12 containing subscales assessing for symptoms of anxiety and depression. Participants rate frequency of occurrences described in the items on a 4 point scale (0- Never, 1- Sometimes, 2- Often, or 3- Always). Sum scores of anxiety/depression items were assessed. Depression items: score range 0-30 Anxiety items: score range 0-18 Higher scores on both the depression & anxiety items indicate higher levels of depression & anxiety. Raw sum scores of both the depression & anxiety subscale items are translated to a T-score. T-scores below 65 represent low severity. T-scores between 65-70 represent medium severity and are on the borderline clinical threshold. T-scores above 70 represent high severity and are above the clinical threshold. A T-score of 50 indicates the population mean with a standard deviation of 10. |
| Change From Baseline in Functional Disability Inventory (Parent) | Assessed at baseline, week 4, and week 8. Score changes from baseline to week 4 and baseline to week 8 are reported. | The Functional Disability Inventory (FDI) Parent questionnaire will be used to assess change in the participants symptoms as rated by the participants parent/guardian. Parents will rank their child's physical trouble or difficulty completing 15 different daily activities (Eating regular meals, Being at school all day, Walking up stairs, etc.) on a scale of 0-4 for each item (0-No trouble, 1- A Little Trouble, 2- Some Trouble, 3- A Lot of Trouble, 4- Impossible). Higher total scores indicate more difficulty functioning due to physical health, based on a sum score of each item. Sum score interpretation cutoffs include: No/Minimal Disability (0-12), Mild Disability (13-20), Moderate Disability (21-29) and Severe Disability (≥30). |
| Change From Baseline in Pain Catastrophizing Scale (Parent) | Assessed at baseline, week 4, and week 8. Score change from baseline to week 8 is reported. | The Pain Catastrophizing Scale Parent form (PCS-P) will be completed by the parent or guardian of the participant. The PCS-P is a proxy questionnaire to the PCS-C, measuring the feelings the parent has when their child is in pain. Parents rate how strongly they feel when their child is in pain on a 5 point scale (0- Not at all, 1- To a slight degree, 2- To a moderate degree, 3- To a great degree, 4- All the time). Sum scores range from 0-52. Higher scores indicate higher levels of pain catastrophizing. A total PCS score of 30 represents a clinically relevant level of catastrophizing. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Active Stimulation (8) Participants will receive active auricular microstimulation via TENS unit for 8 weeks.
Under guidance from the study team, participants will self-administer the TENS therapy for two 1-hour periods a day for 8 weeks.
Transcutaneous Electrical Nerve Stimulation (TENS): Active Transcutaneous Auricular Microstimulation delivered by TENS device | 4 |
| Sham Stimulation (4), Active (4) Participants will receive sham therapy via inactive TENS unit for 4 weeks, followed by active auricular microstimulation via TENS for 4 weeks.
Under guidance from the study team, participants will self-administer the TENS therapy for two 1-hour periods a day for 8 weeks (4 weeks of therapy with inactive TENS, 4 weeks with active TENS).
Transcutaneous Electrical Nerve Stimulation (TENS): Active Transcutaneous Auricular Microstimulation delivered by TENS device
Sham Transcutaneous Electrical Nerve Stimulation: Sham therapy will be delivered by applying the TENS device with non-conductive electrodes so that no microstimulation is delivered | 4 |
| Total | 8 |
Baseline characteristics
| Characteristic | Sham Stimulation (4), Active (4) | Total | Active Stimulation (8) |
|---|---|---|---|
| Age, Continuous | 15.3 years | 15.8 years | 16 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 4 Participants | 8 Participants | 4 Participants |
| Sex: Female, Male Female | 4 Participants | 8 Participants | 4 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 5 | 0 / 5 | 0 / 5 |
| other Total, other adverse events | 1 / 5 | 0 / 5 | 0 / 5 |
| serious Total, serious adverse events | 0 / 5 | 0 / 5 | 0 / 5 |
Outcome results
Change in Blood Cytokines Measured by TNF α Levels at 4 Weeks
Blood will be analyzed to detect changes in protein cytokine TNF α levels, an indicator for inflammation.
Time frame: Assessed at baseline, week 4, and week 8. Change in baseline to week 4 is reported.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Active Stimulation (8) | Change in Blood Cytokines Measured by TNF α Levels at 4 Weeks | -0.237 pg/mL | Standard Deviation 0.888 |
| Sham Stimulation (4), Active (4) | Change in Blood Cytokines Measured by TNF α Levels at 4 Weeks | -2.15 pg/mL | Standard Deviation 3.8 |
Change in Blood Cytokines Measured by TNF α Levels at 8 Weeks
Blood will be analyzed to detect changes in protein cytokine TNF α levels, an indicator for inflammation
Time frame: Assessed at baseline, week 4, and week 8. Change in baseline to week 8.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Active Stimulation (8) | Change in Blood Cytokines Measured by TNF α Levels at 8 Weeks | -0.600 pg/mL | Standard Deviation 3.17 |
| Sham Stimulation (4), Active (4) | Change in Blood Cytokines Measured by TNF α Levels at 8 Weeks | -1.35 pg/mL | — |
Change in Heart Rate Variability at 4 Weeks
EKG tracing will be used to analyze Heart Rate Variability as an indirect measure of vagal nerve output and central autonomic control.
Time frame: Assessed at baseline, week 4, and week 8. Change in baseline to week 4 is reported.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Active Stimulation (8) | Change in Heart Rate Variability at 4 Weeks | Standing | -639 milliseconds (ms)^2 | Standard Deviation 988 |
| Active Stimulation (8) | Change in Heart Rate Variability at 4 Weeks | Supine | 5360 milliseconds (ms)^2 | Standard Deviation 11500 |
| Sham Stimulation (4), Active (4) | Change in Heart Rate Variability at 4 Weeks | Supine | -5440 milliseconds (ms)^2 | Standard Deviation 9340 |
| Sham Stimulation (4), Active (4) | Change in Heart Rate Variability at 4 Weeks | Standing | -264 milliseconds (ms)^2 | Standard Deviation 244 |
Change in Heart Rate Variability at 8 Weeks
EKG tracing will be used to analyze Heart Rate Variability as an indirect measure of vagal nerve output and central autonomic control.
Time frame: Assessed at baseline, week 4, and week 8. Change in baseline to week 8 is reported.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Active Stimulation (8) | Change in Heart Rate Variability at 8 Weeks | Standing | -678 milliseconds (ms)^2 | Standard Deviation 1520 |
| Active Stimulation (8) | Change in Heart Rate Variability at 8 Weeks | Supine | 1640 milliseconds (ms)^2 | Standard Deviation 3750 |
| Sham Stimulation (4), Active (4) | Change in Heart Rate Variability at 8 Weeks | Standing | -65.9 milliseconds (ms)^2 | Standard Deviation 613 |
| Sham Stimulation (4), Active (4) | Change in Heart Rate Variability at 8 Weeks | Supine | -8550 milliseconds (ms)^2 | Standard Deviation 11200 |
Change in Mitochondrial Bioenergetics Measured by Basal Oxygen Consumption Rate at 4 Weeks (Basal Consumption)
Blood draw will be tested for mitochondrial function by Seahorse assay, which measures Basal Oxygen Consumption Rate of live cells to provide insight into mitochondrial activity.
Time frame: Assessed at baseline, week 4, and week 8. Change in baseline to week 4 is reported.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Active Stimulation (8) | Change in Mitochondrial Bioenergetics Measured by Basal Oxygen Consumption Rate at 4 Weeks (Basal Consumption) | 19.5 pmol/min/μg of protein | Standard Deviation 27 |
| Sham Stimulation (4), Active (4) | Change in Mitochondrial Bioenergetics Measured by Basal Oxygen Consumption Rate at 4 Weeks (Basal Consumption) | 6.47 pmol/min/μg of protein | Standard Deviation 26.5 |
Change in Mitochondrial Bioenergetics Measured by Basal Oxygen Consumption Rate at 8 Weeks (Basal Consumption)
Blood draw will be tested for mitochondrial function by Seahorse assay, which measures Basal Oxygen Consumption Rate of live cells to provide insight into mitochondrial activity.
Time frame: Assessed at baseline, week 4, and week 8. Change in baseline to week 8 is reported.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Active Stimulation (8) | Change in Mitochondrial Bioenergetics Measured by Basal Oxygen Consumption Rate at 8 Weeks (Basal Consumption) | 35.3 pmol/min/μg of protein | Standard Deviation 7.6 |
| Sham Stimulation (4), Active (4) | Change in Mitochondrial Bioenergetics Measured by Basal Oxygen Consumption Rate at 8 Weeks (Basal Consumption) | 31 pmol/min/μg of protein | — |
Change From Baseline in Functional Disability Inventory (Child and Adolescent)
The Functional Disability Inventory (FDI) Child and Adolescent questionnaire will be used to assess change in symptoms. Participants will rank physical trouble or difficulty completing 15 different daily activities (Eating regular meals, Being at school all day, Walking up stairs, etc.) on a scale of 0-4 for each item (0-No trouble, 1- A Little Trouble, 2- Some Trouble, 3- A Lot of Trouble, 4- Impossible). Higher total scores indicate more difficulty functioning due to physical health, based on a sum score of each item. Sum score interpretation cutoffs include: No/Minimal Disability (0-12), Mild Disability (13-20), Moderate Disability (21-29) and Severe Disability (≥30).
Time frame: Assessed at baseline, week 4, and week 8. Score changes from baseline to week 4 and baseline to week 8 are reported.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Active Stimulation (8) | Change From Baseline in Functional Disability Inventory (Child and Adolescent) | Change from baseline to 4 weeks | -3.5 Score on a scale | Standard Deviation 10.2 |
| Active Stimulation (8) | Change From Baseline in Functional Disability Inventory (Child and Adolescent) | Change from baseline to 8 weeks | -2.50 Score on a scale | Standard Deviation 9.95 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Functional Disability Inventory (Child and Adolescent) | Change from baseline to 4 weeks | 0.75 Score on a scale | Standard Deviation 0.957 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Functional Disability Inventory (Child and Adolescent) | Change from baseline to 8 weeks | 1.00 Score on a scale | Standard Deviation 1 |
Change From Baseline in Functional Disability Inventory (Parent)
The Functional Disability Inventory (FDI) Parent questionnaire will be used to assess change in the participants symptoms as rated by the participants parent/guardian. Parents will rank their child's physical trouble or difficulty completing 15 different daily activities (Eating regular meals, Being at school all day, Walking up stairs, etc.) on a scale of 0-4 for each item (0-No trouble, 1- A Little Trouble, 2- Some Trouble, 3- A Lot of Trouble, 4- Impossible). Higher total scores indicate more difficulty functioning due to physical health, based on a sum score of each item. Sum score interpretation cutoffs include: No/Minimal Disability (0-12), Mild Disability (13-20), Moderate Disability (21-29) and Severe Disability (≥30).
Time frame: Assessed at baseline, week 4, and week 8. Score changes from baseline to week 4 and baseline to week 8 are reported.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Active Stimulation (8) | Change From Baseline in Functional Disability Inventory (Parent) | Change from baseline to week 4 | -6.25 Score on a scale | Standard Deviation 5.12 |
| Active Stimulation (8) | Change From Baseline in Functional Disability Inventory (Parent) | Change from baseline to week 8 | -3.67 Score on a scale | Standard Deviation 9.29 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Functional Disability Inventory (Parent) | Change from baseline to week 4 | -2.5 Score on a scale | Standard Deviation 1.73 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Functional Disability Inventory (Parent) | Change from baseline to week 8 | -8 Score on a scale | Standard Deviation 7.96 |
Change From Baseline in Pain Catastrophizing Scale (Child)
The Pain Catastrophizing Scale Child form (PCS-C) will be completed by the participant. The PCS-C is a modification of the adult Pain Catastrophizing Scale for use in children, measuring pain-related cognitions and the dimensions of helplessness, rumination and magnification. Participants rate how strong their feelings are about pain on a 5 point scale (0- Not at all, 1- To a slight degree, 2- To a moderate degree, 3- To a great degree, 4- All the time). Sum scores range from 0-52. Higher scores indicate higher levels of pain catastrophizing. A total PCS score of 30 represents a clinically relevant level of catastrophizing.
Time frame: Assessed at baseline, week 4, and week 8. Score change in baseline to week 8 is reported.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Active Stimulation (8) | Change From Baseline in Pain Catastrophizing Scale (Child) | 2.5 Score on a scale | Standard Deviation 9.11 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Pain Catastrophizing Scale (Child) | -0.0667 Score on a scale | Standard Deviation 9.5 |
Change From Baseline in Pain Catastrophizing Scale (Parent)
The Pain Catastrophizing Scale Parent form (PCS-P) will be completed by the parent or guardian of the participant. The PCS-P is a proxy questionnaire to the PCS-C, measuring the feelings the parent has when their child is in pain. Parents rate how strongly they feel when their child is in pain on a 5 point scale (0- Not at all, 1- To a slight degree, 2- To a moderate degree, 3- To a great degree, 4- All the time). Sum scores range from 0-52. Higher scores indicate higher levels of pain catastrophizing. A total PCS score of 30 represents a clinically relevant level of catastrophizing.
Time frame: Assessed at baseline, week 4, and week 8. Score change from baseline to week 8 is reported.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Active Stimulation (8) | Change From Baseline in Pain Catastrophizing Scale (Parent) | -5.67 Score on a scale | Standard Deviation 7.51 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Pain Catastrophizing Scale (Parent) | -3.0 Score on a scale | Standard Deviation 9.42 |
Change From Baseline in Revised Child Anxiety and Depression Scale
The Revised Child Anxiety and Depression Scale (RCADS) assesses children grades 3 to 12 containing subscales assessing for symptoms of anxiety and depression. Participants rate frequency of occurrences described in the items on a 4 point scale (0- Never, 1- Sometimes, 2- Often, or 3- Always). Sum scores of anxiety/depression items were assessed. Depression items: score range 0-30 Anxiety items: score range 0-18 Higher scores on both the depression & anxiety items indicate higher levels of depression & anxiety. Raw sum scores of both the depression & anxiety subscale items are translated to a T-score. T-scores below 65 represent low severity. T-scores between 65-70 represent medium severity and are on the borderline clinical threshold. T-scores above 70 represent high severity and are above the clinical threshold. A T-score of 50 indicates the population mean with a standard deviation of 10.
Time frame: Assessed at baseline, week 4, and week 8. Changes in generalized anxiety & depression t-scores (translated from raw subscale scores) in baseline to week 4 and baseline to week 8 are reported.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Active Stimulation (8) | Change From Baseline in Revised Child Anxiety and Depression Scale | Change from Baseline to 8 weeks- Major Depression Subscale | 0.75 T-score | Standard Deviation 0.957 |
| Active Stimulation (8) | Change From Baseline in Revised Child Anxiety and Depression Scale | Change from Baseline to 8 weeks- Generalized Anxiety Subscale | 1.00 T-score | Standard Deviation 1.83 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Revised Child Anxiety and Depression Scale | Change from Baseline to 8 weeks- Major Depression Subscale | -2.00 T-score | Standard Deviation 3 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Revised Child Anxiety and Depression Scale | Change from Baseline to 8 weeks- Generalized Anxiety Subscale | 0.333 T-score | Standard Deviation 0.577 |
Change From Baseline in Symptom Intensity Questionnaire
Symptom Intensity Questionnaire score will be used to identify the most prominent 5 complaints, with intensity rated on a 10-point centimeter Likert scale. Participants write up to 5 of their most severe symptoms, and then rate those symptoms' severity from none (0) to worst you can possibly imagine (10) by placing a vertical line on the scale. Higher symptom ratings reflect higher symptom intensity & frequency. A 1-3 frequency level is a minimum level and indicates symptoms are occasional. A 4-6 frequency is a moderate level, meaning that symptoms are intermittent, coming and going. A 7-8 frequency is an indication that the symptoms are present more often than not but still not constant. A 9-10 frequency level is severe and indicates that symptoms are constant. The electronic data capture system's field validation used during the study automatically translated the participant-facing 0-10 slider scale placement into a score of 0-100, hence the reported mean values of over 10.
Time frame: Assessed at baseline, week 4, and week 8. Changes per symptom score in baseline to week 4 and baseline to week 8 are reported.
Population: Only one participant reported a Symptom 5 Intensity at Week 4, as well as Symptoms 3, 4, and 5 Intensity at Week 8, therefore no Standard Deviation could be calculated for these results.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Active Stimulation (8) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 2- Change from baseline to week 4 | 21 Centimeters on a slider scale | Standard Deviation 27.4 |
| Active Stimulation (8) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 5- Change from baseline to week 4 | 20 Centimeters on a slider scale | — |
| Active Stimulation (8) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 1- Change from baseline to week 4 | 26 Centimeters on a slider scale | Standard Deviation 29.7 |
| Active Stimulation (8) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 1- Change from baseline to week 8 | 78.7 Centimeters on a slider scale | Standard Deviation 11 |
| Active Stimulation (8) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 3- Change from baseline to week 4 | -2.67 Centimeters on a slider scale | Standard Deviation 12.1 |
| Active Stimulation (8) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 3- Change from baseline to week 8 | 30 Centimeters on a slider scale | — |
| Active Stimulation (8) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 4- Change from baseline to week 8 | 65 Centimeters on a slider scale | — |
| Active Stimulation (8) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 4- Change from baseline to week 4 | -5 Centimeters on a slider scale | Standard Deviation 14.1 |
| Active Stimulation (8) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 5- Change from baseline to week 8 | 72 Centimeters on a slider scale | — |
| Active Stimulation (8) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 2- Change from baseline to week 8 | 60.5 Centimeters on a slider scale | Standard Deviation 38.9 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 5- Change from baseline to week 8 | 70 Centimeters on a slider scale | — |
| Sham Stimulation (4), Active (4) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 2- Change from baseline to week 8 | 15.3 Centimeters on a slider scale | Standard Deviation 18.6 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 1- Change from baseline to week 4 | 6.75 Centimeters on a slider scale | Standard Deviation 19.2 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 2- Change from baseline to week 4 | 4.25 Centimeters on a slider scale | Standard Deviation 37.1 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 3- Change from baseline to week 4 | 26.7 Centimeters on a slider scale | Standard Deviation 33.3 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 4- Change from baseline to week 4 | -9.5 Centimeters on a slider scale | Standard Deviation 0.707 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 5- Change from baseline to week 4 | -10 Centimeters on a slider scale | — |
| Sham Stimulation (4), Active (4) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 1- Change from baseline to week 8 | 41.5 Centimeters on a slider scale | Standard Deviation 33.1 |
| Sham Stimulation (4), Active (4) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 3- Change from baseline to week 8 | 15 Centimeters on a slider scale | — |
| Sham Stimulation (4), Active (4) | Change From Baseline in Symptom Intensity Questionnaire | Symptom 4- Change from baseline to week 8 | 40 Centimeters on a slider scale | — |